Regulation of m6A Methylation as a New Therapeutic Option against COVID-19

The rapid spread of SARS-CoV-2 and the resulting pandemic has led to a spasmodic search for approaches able to limit the diffusion of the disease. The epigenetic machinery has aroused considerable interest in the last decades, and much evidence has demonstrated that this type of modification could r...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Carla Zannella, Luca Rinaldi, Giovanni Boccia, Annalisa Chianese, Ferdinando Carlo Sasso, Francesco De Caro, Gianluigi Franci, Massimiliano Galdiero
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	SARS-CoV-2 COVID-19 epigenetics methylation m6A rhein Medicine R Pharmacy and materia medica RS1-441
Acceso en línea:	https://doaj.org/article/a15887ae802c47cfbb03997ac9fe8272
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:a15887ae802c47cfbb03997ac9fe8272
record_format	dspace
spelling	oai:doaj.org-article:a15887ae802c47cfbb03997ac9fe82722021-11-25T18:39:37ZRegulation of m6A Methylation as a New Therapeutic Option against COVID-1910.3390/ph141111351424-8247https://doaj.org/article/a15887ae802c47cfbb03997ac9fe82722021-11-01T00:00:00Zhttps://www.mdpi.com/1424-8247/14/11/1135https://doaj.org/toc/1424-8247The rapid spread of SARS-CoV-2 and the resulting pandemic has led to a spasmodic search for approaches able to limit the diffusion of the disease. The epigenetic machinery has aroused considerable interest in the last decades, and much evidence has demonstrated that this type of modification could regulate the early stages of viral infection. Recently it was reported that N6-methyladenosine (m6A) influences SARS-CoV-2 replication, although its role remains to be further investigated. The knockdown of enzymes involved in the m6A pathway could represent an optimal strategy to deepen the epigenetic mechanism. In the present study, we blocked the catalytic activity of the fat mass and obesity-associated protein (FTO) by using the selective inhibitor rhein. We observed a strong broad-spectrum reduction of infectivity caused by various coronaviruses, including SARS-CoV-2. This effect could be due to the modulation of m6A levels and could allow identification of this modification as a new therapeutic target to treat SARS-CoV-2 infection.Carla ZannellaLuca RinaldiGiovanni BocciaAnnalisa ChianeseFerdinando Carlo SassoFrancesco De CaroGianluigi FranciMassimiliano GaldieroMDPI AGarticleSARS-CoV-2COVID-19epigeneticsmethylationm6ArheinMedicineRPharmacy and materia medicaRS1-441ENPharmaceuticals, Vol 14, Iss 1135, p 1135 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	SARS-CoV-2 COVID-19 epigenetics methylation m6A rhein Medicine R Pharmacy and materia medica RS1-441
spellingShingle	SARS-CoV-2 COVID-19 epigenetics methylation m6A rhein Medicine R Pharmacy and materia medica RS1-441 Carla Zannella Luca Rinaldi Giovanni Boccia Annalisa Chianese Ferdinando Carlo Sasso Francesco De Caro Gianluigi Franci Massimiliano Galdiero Regulation of m6A Methylation as a New Therapeutic Option against COVID-19
description	The rapid spread of SARS-CoV-2 and the resulting pandemic has led to a spasmodic search for approaches able to limit the diffusion of the disease. The epigenetic machinery has aroused considerable interest in the last decades, and much evidence has demonstrated that this type of modification could regulate the early stages of viral infection. Recently it was reported that N6-methyladenosine (m6A) influences SARS-CoV-2 replication, although its role remains to be further investigated. The knockdown of enzymes involved in the m6A pathway could represent an optimal strategy to deepen the epigenetic mechanism. In the present study, we blocked the catalytic activity of the fat mass and obesity-associated protein (FTO) by using the selective inhibitor rhein. We observed a strong broad-spectrum reduction of infectivity caused by various coronaviruses, including SARS-CoV-2. This effect could be due to the modulation of m6A levels and could allow identification of this modification as a new therapeutic target to treat SARS-CoV-2 infection.
format	article
author	Carla Zannella Luca Rinaldi Giovanni Boccia Annalisa Chianese Ferdinando Carlo Sasso Francesco De Caro Gianluigi Franci Massimiliano Galdiero
author_facet	Carla Zannella Luca Rinaldi Giovanni Boccia Annalisa Chianese Ferdinando Carlo Sasso Francesco De Caro Gianluigi Franci Massimiliano Galdiero
author_sort	Carla Zannella
title	Regulation of m6A Methylation as a New Therapeutic Option against COVID-19
title_short	Regulation of m6A Methylation as a New Therapeutic Option against COVID-19
title_full	Regulation of m6A Methylation as a New Therapeutic Option against COVID-19
title_fullStr	Regulation of m6A Methylation as a New Therapeutic Option against COVID-19
title_full_unstemmed	Regulation of m6A Methylation as a New Therapeutic Option against COVID-19
title_sort	regulation of m6a methylation as a new therapeutic option against covid-19
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/a15887ae802c47cfbb03997ac9fe8272
work_keys_str_mv	AT carlazannella regulationofm6amethylationasanewtherapeuticoptionagainstcovid19 AT lucarinaldi regulationofm6amethylationasanewtherapeuticoptionagainstcovid19 AT giovanniboccia regulationofm6amethylationasanewtherapeuticoptionagainstcovid19 AT annalisachianese regulationofm6amethylationasanewtherapeuticoptionagainstcovid19 AT ferdinandocarlosasso regulationofm6amethylationasanewtherapeuticoptionagainstcovid19 AT francescodecaro regulationofm6amethylationasanewtherapeuticoptionagainstcovid19 AT gianluigifranci regulationofm6amethylationasanewtherapeuticoptionagainstcovid19 AT massimilianogaldiero regulationofm6amethylationasanewtherapeuticoptionagainstcovid19
_version_	1718410853206720512

Regulation of m6A Methylation as a New Therapeutic Option against COVID-19

Ejemplares similares